Back to Search

REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

  • Protocol Number: 202206049
  • Principal Investigator: Ma, Cynthia
  • Cancer Types: Breast

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions